image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

An amendment to the SC 13G filing

SC 13G/A View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

144 View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Report of unscheduled material events or corporate event

8-K EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Data provided by Kaleidoscope.